Look out Alexion, Roche breaks out the details on its rival rare CNS drug
Months after Alexion scored the first-ever approval for patients with neuromyelitis optica spectrum disorder (NMSOD) — researchers at Roche have come out with detailed data on their rival experimental drug satralizumab for use in the rare central nervous system disorder.
The 95-patient study dubbed SAkuraStar tested satralizumab against a placebo. Data showed satralizumab monotherapy conferred a 55% reduction in the risk of relapses compared to placebo in the overall population, representative of NMOSD patients (p=0.0184). In the overall satralizumab-treated population, 76.1% were relapse-free at 48 weeks, and 72.1% relapse-free at 96 weeks, versus 61.9% and 51.2% with placebo, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.